Monoclonal antibodies (mAbs) are attractive therapeutic tools, being highly specific for their targets. However, immunogenicity—the potential of a therapeutic antibody to provoke an immune response—remains a risk.
What is Immunogenicity?
Immunogenicity refers to the immune system’s recognition of a therapeutic antibody as foreign, leading to the production of anti-drug antibodies (ADAs). These ADAs can neutralize the therapeutic efficacy, alter pharmacokinetics, and even cause adverse immune responses. Factors influencing immunogenicity are categorized as:
Extrinsic Factors: Aggregates, contaminants, or co-administered medications that trigger immune responses.
Intrinsic Factors: The molecular structure of the antibody, including variable (V) regions and glycosylation patterns, which can harbor immunogenic epitopes.
Humanization and Fully Human Antibodies
Therapeutic antibodies have evolved through several generations:
Murine Antibodies: Derived from mice, these showed efficacy but caused significant immunogenic responses in humans due to their foreign origin.
Chimeric Antibodies: Featuring human constant regions combined with murine variable regions, these were less immunogenic but not without risk.
Humanized Antibodies: Retaining murine CDRs within human frameworks, these reduced immunogenicity further while maintaining specificity.
Fully Human Antibodies: Developed through phage display or transgenic mice, these antibodies have entirely human amino acid sequences, drastically lowering immunogenicity.
The Root Cause of Immunogenicity
The immunogenicity of therapeutic antibodies often arises from their CDR (complementarity-determining regions)—the regions responsible for antigen binding. These CDRs can harbor CD4+ T cell epitopes, which are linear peptide fragments recognized by the patient’s immune system. When presented by HLA class II molecules, these epitopes activate CD4+ T cells, initiating a cascade that produces ADAs.
Explore Biointron’s AbDrop Service
Our High-throughput Fully Human Antibody Discovery Platform integrates Cyagen’s HUGO-Ab™ mice with Biointron’s AbDrop™ microdroplet-based single B cell screening. This powerful combination accelerates the discovery and development of fully human antibodies, reducing the time from target identification to therapeutic candidate to just three months. Learn more about the service here.
References:
Harding, F. A., Stickler, M. M., Razo, J., & DuBridge, R. B. (2010). The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. MAbs, 2(3), 256. https://doi.org/10.4161/mabs.2.3.11641
DOI: 10.3389/fbioe.2022.856049Antibodies have become essential tools for the diagnosis and treatment of numerous human diseases. However, non-human antibodies, such as those derived from murine sources, often provoke human anti-mouse antibody (HAMA) responses. This immunogenicity leads to rapid clea
In therapeutic antibody development, achieving high-affinity antigen binding is central to improving drug efficacy, durability, and safety.Biointron’s High-Throughput Fully Human Antibody Discovery service is designed to meet this need by integrating advanced screening and engineering technol
I. Introduction to Hybridoma TechnologyHybridoma technology, developed by Köhler and Milstein in 1975, is a foundational method for producing monoclonal antibodies (mAbs). The approach involves fusing antibody-producing B lymphocytes with immortal myeloma cells to form hybridoma cells. These hybrid
Introduction to Monoclonal Antibody Discovery Monoclonal antibodies (mAbs) are one of the most successful classes of biologic drugs on the global pharmaceutical market. Since the approval of Orthoclone OKT3 in 1986, over 100 mAbs have been approved by the U.S. FDA for indications incl
ScientistとScience Exchangeとのご利用可能です。
